Zevra Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Zevra Therapeutics, Inc. (ZVRA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 3.98 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-03-12
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 48.07M shares, a 80.04% increase year-over-year.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-03-31 was 26.70M shares, a 80.52% increase year-over-year.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2018-12-31 was 25.56M shares, a 74.40% increase year-over-year.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2018-09-30 was 16.03M shares, a 9.39% increase year-over-year.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 3.98M shares, a 114.79% increase from fiscal 2019.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 1.85M shares, a 89.66% decline from fiscal 2018.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 17.93M shares, a 22.37% increase from fiscal 2017.
- Zevra Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 14.65M shares, a 0.38% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | 3.98M shares 10-K · filed 2021-03-12 | ||||
| 2020-03-31 | 48.07M shares 10-Q · filed 2020-05-13 | ||||
| 2019-12-31 | 1.85M shares 10-K · filed 2021-03-12 | 29.65M shares 10-K · filed 2020-02-28 | |||
| 2019-03-31 | 26.70M shares 10-Q · filed 2020-05-13 | 26.13M shares derived: average of 2 quarters · filed 2020-05-13 | 22.77M shares derived: average of 3 quarters · filed 2020-05-13 | ||
| 2018-12-31 | 25.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | 20.80M shares derived: average of 2 quarters · filed 2020-02-28 | 17.93M shares 10-K · filed 2020-02-28 | ||
| 2018-09-30 | 16.03M shares 10-Q · filed 2018-11-09 | 15.39M shares 10-Q · filed 2018-11-09 | |||
| 2018-03-31 | 14.79M shares 10-Q · filed 2019-05-14 | 14.72M shares derived: average of 2 quarters · filed 2019-05-14 | 14.70M shares derived: average of 3 quarters · filed 2019-05-14 | ||
| 2017-12-31 | 14.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | 14.66M shares derived: average of 2 quarters · filed 2019-03-01 | 14.65M shares 10-K · filed 2019-03-01 | ||
| 2017-09-30 | 14.66M shares 10-Q · filed 2018-11-09 | 14.65M shares 10-Q · filed 2018-11-09 | |||
| 2017-03-31 | 14.65M shares 10-Q · filed 2018-05-11 | 14.65M shares derived: average of 2 quarters · filed 2018-05-11 | 14.65M shares derived: average of 3 quarters · filed 2018-05-11 | ||
| 2016-12-31 | 14.65M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | 14.65M shares derived: average of 2 quarters · filed 2018-03-30 | 14.60M shares 10-K · filed 2018-03-30 | ||
| 2016-09-30 | 14.65M shares 10-Q · filed 2017-11-09 | 14.58M shares 10-Q · filed 2017-11-09 | |||
| 2016-03-31 | 14.50M shares 10-Q · filed 2017-05-22 | 7.52M shares derived: average of 2 quarters · filed 2018-03-30 | 9.76M shares derived: average of 3 quarters · filed 2018-03-30 | 10.36M shares derived: average of 4 quarters · filed 2018-03-30 | |
| 2015-12-31 | 545.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | 7.39M shares derived: average of 2 quarters · filed 2018-03-30 | 8.98M shares derived: average of 3 quarters · filed 2018-03-30 | 7.37M shares 10-K · filed 2018-03-30 | |
| 2015-09-30 | 14.23M shares 10-Q · filed 2016-11-10 | 13.19M shares derived: average of 2 quarters · filed 2016-11-10 | 9.64M shares 10-Q · filed 2016-11-10 | 7.79M shares derived: average of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | 12.16M shares 10-Q · filed 2015-08-14 | 7.27M shares 10-Q · filed 2015-08-14 | 5.64M shares derived: average of 3 quarters · filed 2017-03-10 | 4.83M shares derived: average of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | 2.39M shares 10-Q · filed 2016-05-13 | 2.38M shares derived: average of 2 quarters · filed 2017-03-10 | 2.38M shares derived: average of 3 quarters · filed 2017-03-10 | 2.38M shares derived: average of 4 quarters · filed 2017-03-10 | |
| 2014-12-31 | 2.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | 2.38M shares derived: average of 2 quarters · filed 2017-03-10 | 2.38M shares derived: average of 3 quarters · filed 2017-03-10 | 2.38M shares 10-K · filed 2017-03-10 | |
| 2014-09-30 | 2.38M shares 10-Q · filed 2015-11-13 | 2.38M shares derived: average of 2 quarters · filed 2015-11-13 | 2.38M shares 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | 2.38M shares 10-Q · filed 2015-08-14 | 2.38M shares 10-Q · filed 2015-08-14 | |||
| 2014-03-31 | 2.38M shares 10-Q · filed 2015-05-29 | ||||
| 2013-12-31 | 2.38M shares 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |